{"preliminary_commentary":{"by_channel":{"x_thread":5},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["sitravatinib","nivolumab"]],"indication":"locally advanced clear cell renal cell carcinoma","name":"NCT03680521","nct_id":"NCT03680521","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03680521. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Sitravatinib oral capsule administered daily 2 weeks alone then in combination with nivolumab administered as 240 mg IV every 2 weeks. Total treatment duration: 6-8 weeks prior to planned nephrectomy.","label":"Sitravatinib and nivolumab","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2023-05-18","type":"ACTUAL"},"conditions":["Clear Cell Renal Cell Carcinoma"],"enrollment":{"count":25,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Sitravatinib","otherNames":[],"type":"DRUG"},{"name":"Nivolumab","otherNames":[],"type":"DRUG"}],"last_update":"2023-10-04","lead_sponsor":"Mirati Therapeutics Inc.","official_title":"A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2020-04-27","type":"ACTUAL"},"primary_outcomes":[{"measure":"Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery","timeFrame":"Baseline to date of surgery (maximum time to surgery was approximately 13 weeks)"},{"measure":"Point in Time Objective Response Prior to Surgery","timeFrame":"Baseline to date of surgery (maximum time to surgery was approximately 13 weeks)"}],"references":[],"start_date":{"date":"2018-10-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT03680521"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03680521"}